

# Crearene

alzchem  
group



**Crearene, Alzchem and University Medical Center of Groningen today announce headline results of a recently concluded clinical study administrating creatine during hemodialysis. Full results with data analysis are expected until end of Q2/2024**

A feasibility-, safety- and dose finding study conducted by a University Medical Center Groningen team with principal investigator Prof. Dr. Stephan J.L. Bakker, supported by Crearene AG, using specially purified creatine provided by the Alzchem group, has recently successfully concluded patient treatment in a double-blind study setting, with four different patient groups and a 3:1 randomization.

The primary endpoint of the study, the demonstration of the technical feasibility of simultaneous creatine administration during hemodialysis treatment, has been met. The study also confirmed that simultaneous administration of creatine during the dialysis process to patients with end stage chronic kidney disease is well tolerated. Furthermore, the study informed on the dose-response curve. Efficacy endpoints, which have been assessed in addition, have been very encouraging with final analysis still to be completed.

Crearene AG and Alzchem Group AG have recently extended their co-operation on developing and commercializing Creavitalis® / creatine-based treatments solutions for dialysis patients. Based on the combination of the patented know-how of Crearene, result of many years of research in the field of creatine, and the manufacturing excellence of Alzchem the partners hope to be able to enable improved treatment options for the more than three million dialysis patients globally.

Weblinks: <https://crearene.com/> and <https://www.alzchem.com/> and <https://www.umcg.nl>